MALDI-TOF Biotyper Sirius

The Department of Health and Human Services Food and Drug Administration Office of Acquisition and Grant Services is soliciting firm-fixed-price quotations for one Bruker MALDI-TOF Biotyper Sirius one GP system to support the Laboratory Response Network's botulinum neurotoxin detection capabilities using the Endopep-MS assay. The procurement seeks to replace obsolete laboratory equipment and eliminate animal testing while enabling high-throughput analysis for rapid response during large-scale public health events. Key contract requirements include delivery of the MALDI-TOF system with the MBT Compass HT Industry Software Package, a dedicated computer workstation meeting specified technical standards, ancillary equipment including a UPS power supply and laser printer, on-site installation, two days of on-site application training, and a minimum one-year full warranty with 48-hour technical support response time. Evaluation criteria emphasize approximately equal weighting between technical approach and price, with the government intending to make award without discussions. The deadline for submitting questions is April 7, 2026, at 12:00 PM ET, and quotations must maintain a 90-calendar-day price validity period from the receipt date.

This solicitation is not designated as a small business set-aside and is issued under Federal Acquisition Regulation Part 12 for commercial products and services. No incumbent contractor or award value has been identified in the solicitation materials. The government requires delivery and full installation at the FDA Moffett Laboratory in Bedford Park, Illinois, within 60 days of contract award. Offerors must submit quotations in two separate volumes—Volume I for technical approach (maximum 10 pages excluding pricing) and Volume II for itemized pricing breakdown—and include GSA schedule contract numbers, System for Award Management Unique Entity IDs, and complete company contact information. The solicitation requires quoters to reference solicitation number 75F40126R00030 and demonstrate the system's capability to support Endopep-MS assays for C. botulinum neurotoxin detection and microorganism identification with FDA-approved specifications.